DOCSLIB.ORG

Participating Company List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Participating Company List Participating Company List Company name Company type(s) Country Synthesis, analytic, diagnostic United States services 3i Diagnostics, Inc. Biotech or pharma, therapeutic United States R&D 60 Degrees Pharmaceuticals Financial, legal, consulting United States Investor (buy-side or sell-side research) Investment bank Other products or services Aagami, Inc. Biotech or pharma, therapeutic United States R&D AbbVie Inc. CMO, CRO United Kingdom Biotech or pharma, animal health Abcam Biotech or pharma, therapeutic South Korea R&D ABL Bio Biotech or pharma, therapeutic United States R&D ACADIA Pharmaceuticals, Inc Biotech or pharma, therapeutic Canada R&D Acasti Pharma Accelera Financial, legal, consulting Canada Biotech or pharma, therapeutic United States R&D Accelerated Biosciences Corp. Accel-Rx Other products or services Canada Biotech or pharma, therapeutic United States R&D Achelios Therapeutics Biotech or pharma, therapeutic United States R&D Aciont Inc Biotech or pharma, therapeutic Australia R&D Actinogen Medical Adan Medical Innovation Medical device or technology Spain Biotech or pharma, animal United States health Other products or services Other R&D services Adare Pharmaceuticals Biotech or pharma, therapeutic United States R&D ADial Pharmaceuticals, LLC Biotech or pharma, therapeutic United States R&D Aduro Biotech Biotech or pharma, therapeutic United States R&D Aequor, Inc. Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Biotech or pharma, therapeutic United States R&D Aeterna Zentaris Biotech or pharma, therapeutic United States R&D Affigen Biotech or pharma, therapeutic Ireland R&D Afimmune Biotech or pharma, therapeutic United States R&D Agenovir Corporation Biotech or pharma, therapeutic United States R&D Agile Sciences Biotech or pharma, therapeutic Japan R&D Biotech or pharma, animal health AIBIOS Co., Ltd. Biotech or pharma, therapeutic Denmark R&D Albumedix Financial, legal, consulting United States ALDEN MARKETING Other products or services COMMUNICATIONS Digital health United States Medical device or technology Biotech or pharma, therapeutic R&D Alexza Pharmaceuticals, Inc Biotech or pharma, therapeutic Japan R&D ALFRESA PHARMA CORP Biotech or pharma, therapeutic United States R&D ALGOMEDIX, Inc. Investor (buy-side or sell-side France research) Financial, legal, consulting Alira Health Investor (buy-side or sell-side United States research) Allied-Bristol Life Sciences Biotech or pharma, therapeutic United States R&D AlloMek Therapeutics Allotrope Medical Medical device or technology United States Biotech or pharma, therapeutic Spain R&D Almirall S.A Biotech or pharma, animal France health Alphanosos Biotech or pharma, therapeutic United States R&D Alpine Immune Sciences Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Other products or services United States Biotech or pharma, therapeutic R&D Other R&D services Altis Biosystems Biotech or pharma, therapeutic Canada R&D Altum Pharmaceuticals Inc. Public, NPO, govt., economic United States Alzheimers Drug Discovery development Foundation AMC Health Medical device or technology United States Biotech or pharma, therapeutic United States R&D Amgen Inc Biotech or pharma, therapeutic United States R&D Amicus Therapeutics, Inc Biotech or pharma, therapeutic Netherlands R&D AM-Pharma BV Biotech or pharma, therapeutic United States R&D AmpliPhi BioSciences Corporation Biotech or pharma, therapeutic United States R&D Amygdala Neurosciences Inc. ANMPARTNERS Financial, legal, consulting France Antenna Other products or services United States Biotech or pharma, therapeutic United States R&D Anthera Pharmaceuticals, Inc Biotech or pharma, therapeutic United States R&D Apexian Pharmaceuticals ApolloBio Corp. China Biotech or pharma, therapeutic Israel R&D Aposense Biotech or pharma, therapeutic United States R&D AptamiR Therapeutics, Inc. Biotech or pharma, animal United States health Apton Biosystems Financial, legal, consulting United States Biotech or pharma, animal health Biotech or pharma, therapeutic R&D Aqua Partners LLC Biotech or pharma, therapeutic United States R&D Aquinnah Pharmaceuticals Biotech or pharma, therapeutic Canada R&D Aquinox Pharmaceuticals, Inc. Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Arix Bioscience United States Other products or services United States Public, NPO, govt., economic development Biotech - industrial & environmental Biotech or pharma, therapeutic R&D Digital health Investor (buy-side or sell-side research) Medical device or technology Patient advocacy Arizona BioIndustry Association Biotech or pharma, therapeutic United States R&D Arrowhead Pharmaceuticals, Inc. Biotech or pharma, therapeutic United States R&D Artery Therapeutics, Inc. Arthroventions, LLC Medical device or technology United States Biotech or pharma, therapeutic United States R&D ArunA Biomedical, Inc. Biotech or pharma, therapeutic Japan R&D Asahi Kasei Pharma Corporation Asajes Biotech or pharma, therapeutic Taiwan R&D Asclepiumm Taiwan Biotech or pharma, therapeutic China R&D Asieris Pharmaceuticals Biotech or pharma, therapeutic Japan R&D Aska Pharmaceutical Co, Ltd Biotech or pharma, therapeutic Canada R&D Aspect Biosystems Ltd Biotech or pharma, therapeutic Japan R&D Astellas Pharma Inc. Biotech or pharma, therapeutic United States R&D Astrocyte Pharmaceuticals Atheneos Capital United States Biotech or pharma, therapeutic United States R&D Atreca, Inc. Biotech or pharma, therapeutic United States R&D Attenua, Inc Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Auburn University Office of Academic, tech transfer United States Innovation Advancement & Commercialization Other products or services United States Audrey Sheppard Women's Health Financial, legal, consulting Consulting Biotech or pharma, therapeutic United States R&D AurimMed Pharma, Inc. Biotech or pharma, therapeutic Switzerland R&D Auris Medical AG Digital health United States CMO, CRO Medical device or technology Aventyn, Inc Biotech or pharma, therapeutic United States R&D AVEO Oncology Biotech or pharma, therapeutic India R&D Other R&D services Avesthagen Limited Biotech or pharma, therapeutic United States R&D Aviragen Therapeutics, Inc. Biotech or pharma, therapeutic United States R&D AVM Biotechnology Biotech or pharma, therapeutic United States R&D Axsome Therapeutics Biotech or pharma, therapeutic United States R&D Azitra Synthesis, analytic, diagnostic United States services Medical device or technology Baebies Baker McKenzie LLP Financial, legal, consulting United States Public, NPO, govt., economic Switzerland development BaselArea Economic Promotion Biotech or pharma, therapeutic Denmark R&D Bavarian Nordic, A/S Biotech or pharma, therapeutic United States R&D BBN Cardio Therapeutics IT, information Switzerland Digital health Medical device or technology Other R&D services BC Platforms Investor (buy-side or sell-side United States research) BDH Capital Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Biotech or pharma, therapeutic United States R&D Beacon Discovery, Inc. Financial, legal, consulting China Investor (buy-side or sell-side research) Beijing Augeas Life Science Investment bank Management Group Biotech or pharma, therapeutic United States R&D Bell Biosystems, Inc Biotech or pharma, therapeutic Norway R&D BerGenBio AS Berkley Life Sciences, LLC Other products or services United States Biotech or pharma, therapeutic Belgium R&D BESINS Healthcare Biotech or pharma, therapeutic United States R&D Beta Cat Pharmaceuticals BICI-USA United States Other products or services United States Financial, legal, consulting BinghamHill Ventures BioBlocks Inc Other products or services United States Biotech or pharma, therapeutic United States R&D BIOCODEX Inc. Biocom Other products or services United States Bio-Com Intl CMO, CRO United States Synthesis, analytic, diagnostic United States services CMO, CRO BioDuro BioGuides Other products or services Public, NPO, govt., economic United Kingdom development Bioindustry Association (BIA) Biotech or pharma, therapeutic United States R&D Medical device or technology Other products or services Financial, legal, consulting Other R&D services CMO, CRO BIOLOGICS CONSULTING Biotech or pharma, therapeutic Brazil R&D Biotech or pharma, animal health BIOLOTUS BIOTECH Participating company list as of November 20, 2017 Participating Company List Company name Company type(s) Country Biotech or pharma, therapeutic United States R&D BioMarker Strategies, LLC Biotech or pharma, therapeutic United States R&D BioMarker, Inc. Biotech or pharma, therapeutic Brazil R&D Biomm S.A. Bionest Partners, Inc. Financial, legal, consulting United States Medical device or technology United States CMO, CRO Bionique Testing Laboratories Biotech or pharma, therapeutic Czech Republic R&D CMO, CRO Bionix Ltd. Financial, legal, consulting United States Biotech or pharma, therapeutic R&D CMO, CRO Other products or services Biopharma Global Biotech or pharma, therapeutic United States R&D BioPharmX BioProcess Technology Consultants Financial, legal, consulting United States Financial, legal, consulting United States Biotech or pharma, therapeutic R&D BioSense Global LLC Biotech or pharma, therapeutic United States R&D Biotech or pharma, animal
Load more

Recommended publications
  • Tetraphase Pharmaceuticals, Inc
    WBB Securities, LLC Steve Brozak, DMH [email protected] (908) 518-7610 Tetraphase Pharmaceuticals, Inc. (NasdaqGS: TTPH) Initiating Coverage Initiating Coverage with a Speculative Buy Rating February 22, 2018 and a 12-Month Price Target of $6.00 Tetraphase Prepares for Commercialization of a Needed Antibiotic Tetraphase Pharmaceuticals, Inc. (TTPH) is Current Price $2.20 a clinical stage pharmaceutical company, 12 Month Target Price $6.00 with eravacycline as its lead candidate. It is a novel tetracycline-derived antibiotic to 12-Month Trading Range $2.05-$9.93 treat resistant and multidrug-resistant Market Capitalization (Mil) $113.50 infections, including multidrug-resistant Shares Outstanding (Mil) 51.59 Gram-negative infections. Following Avg. Daily Volume 872,642 successful IGNITE1 and IGNITE4 Phase 3 L.T. Debt (Mil) 0.00 trials in complicated intra-abdominal infections (cIAI), a New Drug Application Dividend/Yield N/A (NDA) was filed with the FDA and a Book Value P/S $2.92 Marketing Authorisation Application (MAA) was submitted to the EMA for IV NASDAQ Composite 7,218.23 eravacycline. S&P 500 2,701.33 Historical Performance and Disclosures on Page 10 - 11 Two days ago, TTPH announced an exclusive Source: QUODD+ licensing agreement with Everest Medicines Limited, a C-bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore (known as the Territories). Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as a maximum of $20.0 million via achieving annual sales milestones.
    [Show full text]
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • 香港知識產權公報hong Kong Intellectual Property Journal
    香港知識產權公報 Hong Kong Intellectual Property Journal 2007年7月27日 27 July 2007 公報編號 Journal No.: 225 公布日期 Publication Date: 27-07-2007 分項名稱 Section Name: 目錄 Contents * 目錄 Contents 根據專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications published under section 20 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按申請人姓名／名稱排列 Arranged by Name of Applicant 根據專利條例第 27 條發表批予標準專利 Granted Standard Patents published under section 27 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名／名稱排列 Arranged by Name of Proprietor 1/336 公報編號 Journal No.: 225 公布日期 Publication Date: 27-07-2007 分項名稱 Section Name: 目錄 Contents 根據專利條例第 118 條發表批予短期專利 Granted Short-term Patents published under section 118 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名／名稱排列 Arranged by Name of Proprietor 根據專利條例(第 514 章)公布的其他公告 Other Notices Published under the Patents Ordinance (Cap. 514) 根據專利條例第 20 條發表後撤回，當作已予撤回或被拒的申請 Applications Withdrawn, Deemed to have been Withdrawn, or Refused, after Publication under section 20 of the Patents Ordinance 根據專利條例第 39 條，標準專利因未繳續期費而停止有效 Standard Patents Ceased through Non-payment of Renewal Fees under section 39 of the Patents Ordinance 根據專利條例第 39(1)(b)條，標準專利
    [Show full text]
  • Ulcerative Colitis
    +44 20 8123 2220 [email protected] Ulcerative Colitis - Pipeline Review, H1 2020 https://marketpublishers.com/r/U44188EFA0EEN.html Date: April 2020 Pages: 671 Price: US$ 2,000.00 (Single User License) ID: U44188EFA0EEN Abstracts Ulcerative Colitis - Pipeline Review, H1 2020 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. REPORT HIGHLIGHTS Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected] involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • Kansas City Regional Life Sciences Industry Census 2018 Executive Summary
    Kansas City Regional Life Sciences Industry Census 2018 Executive Summary ................................................................................................................... 4 Background ................................................................................................................................ 7 Methodology .............................................................................................................................. 8 Industry Presence, Overview & Analysis ...................................................................................12 Introduction ...........................................................................................................................12 Presence and Overview ........................................................................................................13 Regional Developments 2016-2018 ...................................................................................13 Life Sciences Capital .........................................................................................................21 Incubators, Accelerators, and New Business Facilities.......................................................25 Universities ........................................................................................................................28 Hospitals ............................................................................................................................32 Analysis .................................................................................................................................33
    [Show full text]
  • Form 13F-HR Filed 2019-02-14
    SECURITIES AND EXCHANGE COMMISSION FORM 13F-HR Initial quarterly Form 13F holdings report filed by institutional managers Filing Date: 2019-02-14 | Period of Report: 2018-12-31 SEC Accession No. 0001567619-19-004367 (HTML Version on secdatabase.com) FILER DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Mailing Address Business Address 780 THIRD AVENUE, 37TH 780 THIRD AVENUE CIK:1009258| IRS No.: 000000000 | State of Incorp.:DE FLOOR 37TH FLOOR Type: 13F-HR | Act: 34 | File No.: 028-05366 | Film No.: 19606038 NEW YORK NY 10017 NEW YORK NY 10017 2125511600 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE OMB Number: 3235-0006 COMMISSION Expires: July 31, 2015 Washington, D.C. 20549 Estimated average burden hours per response: 23.8 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: 12-31-2018 Check here if Amendment: ☐ Amendment Number: This Amendment (Check only one.): ☐ is a restatement. ☐ adds new holdings entries. Institutional Investment Manager Filing this Report: Name: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Address: 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017 Form 13F File Number: 028-05366 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: James E.
    [Show full text]
  • Onbiovc Trend Analysis
    O N B IO V C TREND ANALYSIS 2009 Bioscience VC, M&A and IPO Overview Key Findings: 352 bioscience venture funded financings raised $6.3 billion The bioscience public markets thawed, welcoming five new issues 25 biopharma M&A transx >$100M accounted for $221.5 billion Publication Date: 15 February 2010 Report Code: IDOB1002 www.onbiovc.com Indicium Data 1630A 30th Street Suite 370 Boulder, CO 80301 USA t: +1 303 902 4413 e: [email protected] twitter @OnBioVC Information contained herein is based on sources the Company believed reliable at time of reporting but is not guaranteed by the Company or its subsidiaries and is not considered all inclusive, no representation is made to accuracy or completeness, and it should not be relied on as such. 2009 ONBIOVC TREND ANALYSIS About OnBioVC O N B IO VC The 2009 OnBioVC Trend Analysis provides timely coverage and comprehensive analysis of global bioscience private and public capital investment and M&A activity. This report parses out transactional activity via the tracking of private bioscience companies (including therapeutic, diagnostic, medical device, medical-IT and biofuel) and details bioscience venture investments over time and compares to prior period trends. OnBioVC, an Indicium Data Company, publishes reports quarterly, this report includes data for year-over-year and year-to-date periods. The venture deal data contained is sorted by aggregate dollars raised via round, region, state and sector, and contains additional information on the indications and technologies receiving investment along with detail on the company who has closed their financing round within the identified time period; this data is followed by an analysis of bioscience public offerings and biopharma M&A deals.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Life Science District
    Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing. unique opportunities for business Pharmaceuticals. And with Denver Which means the opportunities for development. The University’s International Airport being only 15 improvement—in the health of Technology Transfer o ce, ranked minutes away, access to both coasts Coloradoans and in the health of among the top 20 universities for takes only a few hours.
    [Show full text]
  • Ensuring U.S. Biopharmaceutical Competitiveness
    Ensuring U.S. Biopharmaceutical Competitiveness STEPHEN EZELL | JULY 2020 If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy. KEY TAKEAWAYS ▪ The biopharmaceutical industry makes important contributions to the U.S. economy, including employing over 500,000 workers making 1.4 times the U.S. earnings average. ▪ The United States leads the world on most indices of R&D investment and innovation. From 2004 to 2018, U.S.-headquartered firms produced almost twice as many new drugs as did firms in Europe, and 3 to 4 times as many as Japan. ▪ Despite U.S. strengths in biopharmaceutical R&D and innovation, manufacturing has dropped. From 2009 to 2018, real value-added output in pharmaceutical and medicines manufacturing fell by nearly one-third. ▪ Partly as a consequence, the U.S. trade balance in pharmaceuticals has grown from a deficit of $16 billion in 2010 to a deficit of $77 billion in 2019. ▪ Calls for reshoring more biopharmaceutical manufacturing should distinguish between mature manufacturing processes and those still evolving, as in continuous process biomanufacturing, where U.S.-based production can enjoy unique strengths. ▪ America must continually bolster its biopharmaceutical leadership position, especially as China implements ever-more aggressive policies to improve their life-sciences competitiveness, not only in production but also in innovation. ▪ To support the sector, policymakers should focus on: 1) maintaining strengths, including in pricing, tech transfer, and intellectual property; 2) spurring domestic innovation; 3) spurring increased domestic production; and 4) combatting foreign mercantilism.
    [Show full text]